| Trial ID: | L5273 |
| Source ID: | NCT02479399
|
| Associated Drug: |
Ipragliflozin
|
| Title: |
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
|
| Acronym: |
STELLALONGTERM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: ipragliflozin
|
| Outcome Measures: |
Primary: Incidence of cardiovascular adverse events, Up to 3 years|Incidence of malignant tumor, Up to 3 years | Secondary: Safety developed by adverse events and laboratory tests, Up to 3 years
|
| Sponsor/Collaborators: |
Sponsor: Astellas Pharma Inc
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
11412
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2014-07-17
|
| Completion Date: |
2018-10-16
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-22
|
| Locations: |
Chubu, Japan|Chugoku, Japan|Hokkaido, Japan|Kansai, Japan|Kantou, Japan|Kyushu, Japan|Shikoku, Japan|Tohoku, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT02479399
|
